Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon Enters Chinese Market With Shanghai Shanyi Partnership

NEW YORK – Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services. 

Ann Arbor, Michigan-based Genomenon said today that the new partnership will allow the company to bring its Mastermind genomic search engine to clinical laboratories in China. 

"Our partnership with Shanghai Shanyi will allow us to expand our footprint in the China market, seamlessly integrating with their other best-of-breed end-to-end clinical [next-generation sequencing] solutions," Genomenon CEO Mike Klein said in a statement.

"We’re proud to bring Mastermind to clinical laboratories in China," added Lei Li, general manager of Shanghai Shanyi. Shanyi said that early work with Genomenon has helped customers reduce the amount of time they spend searching for variants of unknown significance by 60 percent to 80 percent.

Genomenon previously operated only in North America and Europe, through partnerships with the likes of US-based LifeMap Sciences, Parabricks, Belgian artificial intelligence vendor Diploid, and others. 

The company raised $2.5 million in private equity early this year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.